To date, more than 7,000 rare diseases affecting 400 million people worldwide including 3 million in France have been identified. There are still no approved treatments for 95% of these diseases. The use of real-world health data and AI may thus lead to major innovations in diagnosis and the identification of therapeutic molecules. The “Artificial Intelligence and Rare Diseases” project thus aims to respond to the strong expectations of patients with rare diseases.
The objective of this project is to develop a concrete example of the use of artificial intelligence in healthcare to contribute to the structuring and competitiveness of the sector and make France a leader in the field of rare diseases.
Through this project, the idea is first to have an interoperable data warehouse in a secure environment to be able to match, standardize and poll public and private data on rare diseases. This initiative will be based on already existing infrastructures, such as the National Data Bank for Rare Diseases (BNDMR), the French health insurance data, the Health Data Hub or the Data Warehouse of the Public Hospitals of Paris (AP-HP).
Thanks to this infrastructure, the aim is to meet a key medical need: shorten diagnostic odyssey and reduce diagnostic dead-end for patients.
Supported by a joint committee composed of representatives of the whole sector, the project governance will be similar to that of the Strategic Committee of the 3rd French National Plan for Rare Diseases
The “AI & Health” Program in the spotlight at the “AI for Health” event ! The “AI for Health” event organized by Janssen and StartupInside on November 10, 2020 welcomed the project leaders and taskeforces from the AI & Health Program of the Strategic Contract for the Healthcare Industry and Health...
En savoir plusFirst Masterclass organized by ARIIS: “The challenges of vaccines” The first Masterclass organized by ARIIS will be held on 15 January 2021 and led by Ms. Soizic Courcier, former Head of GSK Europe Vaccinology division, who will share her vision and expertise on the challenges of vaccines regarding clinical development,...
En savoir plusThe “HYBRID 2021” event under preparation! For the first time, ARIIS, AVIESAN, Leem, Bpifrance and France Biotech are joining their forces to create a new event: HYBRID. As a result of a merger between the Rencontres Internationales de la Recherche and the Rencontres Internationales des Biotechnologies, HYBRID aims to gather...
En savoir plus